G

Genovis AB
STO:GENO

Watchlist Manager
Genovis AB
STO:GENO
Watchlist
Price: 28.05 SEK 3.13% Market Closed
Market Cap: 1.8B SEK
Have any thoughts about
Genovis AB?
Write Note

Genovis AB
Other Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genovis AB
Other Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
G
Genovis AB
STO:GENO
Other Operating Expenses
-kr748k
CAGR 3-Years
55%
CAGR 5-Years
42%
CAGR 10-Years
N/A
AddLife AB
STO:ALIF B
Other Operating Expenses
kr230m
CAGR 3-Years
112%
CAGR 5-Years
85%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Other Operating Expenses
kr218m
CAGR 3-Years
146%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotage AB
STO:BIOT
Other Operating Expenses
-kr11m
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
MedCap AB (publ)
STO:MCAP
Other Operating Expenses
kr24.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Magle Chemoswed Holding AB
STO:MAGLE
Other Operating Expenses
-kr40.5m
CAGR 3-Years
-3%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
No Stocks Found

Genovis AB
Glance View

Market Cap
1.8B SEK
Industry
Life Sciences Tools & Services

Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

GENO Intrinsic Value
24.64 SEK
Overvaluation 12%
Intrinsic Value
Price
G

See Also

What is Genovis AB's Other Operating Expenses?
Other Operating Expenses
-748k SEK

Based on the financial report for Jun 30, 2024, Genovis AB's Other Operating Expenses amounts to -748k SEK.

What is Genovis AB's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 5Y
42%

Over the last year, the Other Operating Expenses growth was 80%. The average annual Other Operating Expenses growth rates for Genovis AB have been 55% over the past three years , 42% over the past five years .

Back to Top